

**UNITED STATES INTERNATIONAL TRADE COMMISSION**  
**Washington, D.C.**

**In the Matter of**  
**CERTAIN HYDRODERMABRASION**  
**SYSTEMS AND COMPONENTS THEREOF III**

**Investigation No. 337-TA-1417**

**NOTICE OF A COMMISSION DETERMINATION NOT TO REVIEW**  
**AN INITIAL DETERMINATION FINDING RESPONDENTS IN DEFAULT**

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the U.S. International Trade Commission (“Commission”) has determined not to review an initial determination (“ID”) (Order No. 13) issued by the presiding administrative law judge (“ALJ”) finding respondents Bio-Infusions USA Inc., MIRAmедtech UG, eMIRAmед USA, LLC, and MIRAmедtech SP. Z.O.O. in default.

**FOR FURTHER INFORMATION CONTACT:** B. Rashmi Borah, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street S.W., Washington, D.C. 20436, telephone (202) 205-2518. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email [EDIS3Help@usitc.gov](mailto:EDIS3Help@usitc.gov). General information concerning the Commission may also be obtained by accessing its Internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205-1810.

**SUPPLEMENTARY INFORMATION:** The Commission instituted this investigation on September 13, 2024, based on a complaint, as supplemented, filed by HydraFacial LLC f/k/a Edge Systems LLC of Long Beach, California (“HydraFacial”). 89 FR 74995-96 (September 13, 2024). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 (“section 337”), based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain hydrodermabrasion systems and components thereof by reason of the infringement of certain claims of U.S. Patent No. 11,446,477 (“the ’477 patent”). *Id.* The complaint also asserts that a domestic industry exists.

The Commission’s notice of investigation names as respondents: Luvo Medical Technologies Inc. of Ontario, Canada; Clarion Medical Technologies, Inc. of Ontario, Canada; Healthcare Markets, Inc. d/b/a Powered by MRP of Park City, Utah; Medical Purchasing Resource, LLC of Little Elm, Texas; Bio-Infusions USA Inc. of Seminole, Florida; MIRAmедtech UG of Neulingen, Germany; eMIRAmед USA, LLC of Irvine, California; and

MIRAmедtech SP. Z.O.O. of Warsaw, Poland. *Id.* The Office of Unfair Import Investigations is not participating in this investigation. *Id.*

On January 2, 2025, the Commission found respondent Medical Purchasing Resource, LLC in default. Order No. 7 (Dec. 9, 2024), *unreviewed by Comm'n Notice* (Jan. 2, 2025).

On December 3, 2024, HydraFacial filed a motion (“Mot.”) requesting that the ALJ issue an order directing respondents Bio-Infusions USA Inc., MIRAmедtech UG, eMIRAmед USA, LLC, and MIRAmедtech SP. Z.O.O. (collectively, “Defaulting Respondents”) to show cause why they should not be found in default for failure to respond to the complaint and notice of investigation. *See Mot.* at 1 (Dec. 3, 2024).

On December 17, 2024, the ALJ issued the requested order directing the Defaulting Respondents to show cause by December 30, 2024, why they should not be found in default. Order No. 9 (Dec. 17, 2024). The ALJ found that the Defaulting Respondents were served the complaint and notice of investigation on various dates in September and November 2024, but that they did not respond to either the complaint or notice of investigation. *Id.* The show cause order was properly served on the Defaulting Respondents. EDIS Doc. ID 839457 (Attachment IDs 2288398, 2293788). No responses were filed.

On January 17, 2025, the ALJ issued the subject ID (Order No. 13) pursuant to Commission Rule 210.16(b)(1)(ii), 19 CFR 210.16(b)(1)(ii), finding the Defaulting Respondents in default. Order No. 13 (Jan. 17, 2025). The ID finds that the Defaulting Respondents failed to make the necessary showing of good cause by failing to “respond to the order to show cause why they should not be found in default and why judgment should not be rendered against them for failing to respond to the complaint and notice of investigation.” ID at 1.

No party filed a petition for review of the subject ID.

The Commission has determined not to review the subject ID (Order No. 13). The Commission finds Bio-Infusions USA Inc., MIRAmедtech UG, eMIRAmед USA, LLC, and MIRAmедtech SP. Z.O.O. to be in default. The Defaulting Respondents have waived their right to appear, to be served with documents, and to contest the allegations at issue in this investigation, pursuant to Commission Rule 210.16(b)(4), 19 CFR 210.16(b)(4).

The Commission vote for this determination took place on February 6, 2025.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission



Lisa R. Barton  
Secretary to the Commission

Issued: February 6, 2025